Lexicon Pharmaceuticals/$LXRX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Ticker
$LXRX
Sector
Primary listing
Employees
103
Headquarters
Website
LXRX Metrics
BasicAdvanced
$501M
-
-$0.33
1.24
-
Price and volume
Market cap
$501M
Beta
1.24
52-week high
$1.66
52-week low
$0.28
Average daily volume
2.4M
Financial strength
Current ratio
4.165
Quick ratio
4.053
Long term debt to equity
46.745
Total debt to equity
47.447
Interest coverage (TTM)
-8.44%
Profitability
EBITDA (TTM)
-105.47
Gross margin (TTM)
-43.39%
Net profit margin (TTM)
-206.43%
Operating margin (TTM)
-181.53%
Revenue per employee (TTM)
$570,000
Management effectiveness
Return on assets (TTM)
-22.14%
Return on equity (TTM)
-65.30%
Valuation
Price to revenue (TTM)
8.557
Price to book
3.87
Price to tangible book (TTM)
5.91
Price to free cash flow (TTM)
-4.87
Free cash flow yield (TTM)
-20.54%
Free cash flow per share (TTM)
-0.283
Growth
Revenue change (TTM)
1,504.83%
Earnings per share change (TTM)
-57.12%
3-year revenue growth (CAGR)
712.35%
10-year revenue growth (CAGR)
9.27%
3-year earnings per share growth (CAGR)
-20.09%
10-year earnings per share growth (CAGR)
-11.18%
What the Analysts think about LXRX
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
Bulls say / Bears say
Novo Nordisk has signed a licensing deal for Lexicon’s obesity drug candidate LX9851 worth up to $1 billion, including $75 million in upfront and near-term payments, affirming Lexicon’s obesity pipeline value and strengthening its financial footing.
Topline Phase 2b PROGRESS results show that pilavapadin (LX9211) at a 10 mg dose delivered meaningful pain relief compared to placebo with good tolerability, supporting its progress to Phase 3 trials.
Lexicon shares nearly doubled in premarket trading following the Novo Nordisk deal, reflecting strong market confidence in its pipeline.
FDA has postponed its review of additional data for Zynquista until Q4 2025, delaying any approval decision and associated revenue opportunities.
A complete response letter from the FDA in December 2024 flagged concerns about a higher risk of diabetic ketoacidosis with Zynquista, weakening confidence in its safety profile.
Lexicon plans to cut approximately 60% of its workforce after FDA shortcomings in its diabetes drug application, which could restrict its commercial and operational capabilities.
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
LXRX Financial Performance
Revenues and expenses
LXRX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexicon Pharmaceuticals stock?
Lexicon Pharmaceuticals (LXRX) has a market cap of $501M as of November 06, 2025.
What is the P/E ratio for Lexicon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Lexicon Pharmaceuticals (LXRX) stock is 0 as of November 06, 2025.
Does Lexicon Pharmaceuticals stock pay dividends?
No, Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders as of November 06, 2025.
When is the next Lexicon Pharmaceuticals dividend payment date?
Lexicon Pharmaceuticals (LXRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals (LXRX) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.